1448858-09-0

Basic information

• Product Name: 5-(2-(hex-5-enyloxy)phenyl)-1-methyl-1H-imidazol-2-amine
• Synonyms: 5-(2-(hex-5-enyloxy)phenyl)-1-methyl-1H-imidazol-2-amine
• CAS NO: 1448858-09-0
• Molecular Weight: 271.362
• Mol File: 1448858-09-0.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 5-(2-(hex-5-enyloxy)phenyl)-1-methyl-1H-imidazol-2-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(2-(hex-5-enyloxy)phenyl)-1-methyl-1H-imidazol-2-amine(1448858-09-0)
• EPA Substance Registry System: 5-(2-(hex-5-enyloxy)phenyl)-1-methyl-1H-imidazol-2-amine(1448858-09-0)

Safety Data

• Hazardous Substances Data: 1448858-09-0(Hazardous Substances Data)

Upstream product

• 821-41-0 5-Hexen-1-ol 
• 931-61-3 N-methylpyrimidin-2-amine 
• 1448858-08-9 2-bromo-1-(2-(hex-5-enyloxy)phenyl)ethanone 
• 64818-36-6 5-hexenyl methanesulfonate 
• 1448858-12-5 1-(2-(hex-5-enyloxy)phenyl)ethanone 

Downstream Products

• 1448857-94-0 N-(5-(2-(hex-5-en-1-yloxy)phenyl)-1-methyl-1H-imidazol-2-yl)hex-5-enamide 

Relevant articles and documents

New 5-aryl-1H-imidazoles display in vitro antitumor activity against apoptosis-resistant cancer models, including melanomas, through mitochondrial targeting

We designed and synthesized 48 aryl-1H-imidazole derivatives and investigated their in vitro growth inhibitory activity in cancer cell lines known to present various levels of resistance to proapoptotic stimuli. The IC50 in vitro growth inhibitory concentration of these compounds ranged from >100 μM to single digit μM. Among the most active compounds, 2i displayed similar in vitro growth inhibition in cancer cells independent of the cells' levels of resistance to proapoptotic stimuli and was found to be cytostatic in melanoma cell lines. Compound 2i was then tested by the National Cancer Institute Human Tumor Cell Line Anti-Cancer Drug Screen, and the NCI COMPARE algorithm did not reveal any correlation between its growth inhibition profiles with the NCI database compound profiles. The use of transcriptomically characterized melanoma models then enabled us to highlight mitochondrial targeting by 2i. This hypothesis was further confirmed by reactive oxygen production measurement and oxygen consumption analysis.